Atypical Haemolytic Uraemic Syndrome Specialised Services for NHS England

Tender description

Atypical haemolytic uraemic syndrome (aHUS) is a chronic, rare, progressive condition that causes severe inflammation of blood vessels and the formation of blood clots in small blood vessels throughout the body, a process known as systemic thrombotic microangiopathy. NHS England is seeking bids from provider(s) that can deliver a service for patients with aHUS that meets the specific terms set out in the NICE guidance, namely: • coordination of eculizumab use through an expert centre; • monitoring systems to record the number of people with a diagnosis of atypical haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment; • a national protocol for starting and stopping eculizumab for clinical reasons; and • a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur. This is intended to be a 5 year contract (3 years with the option to extend for a further 2 years) The procurement for this service is being carried out as an open process. For access to the ITT, please go to the following link: https://ardengemcsu.bravosolution.co.uk/web/login.html?_ncp=1445004116405.32418-1 If you have any queries, please contact Carey Bovington, Procurement Manager, at carey.bovington@ardengemcsu.nhs.uk